NNVC: A Once-in-a-Decade Antiviral Breakthrough Is Emerging

From Deadly Flu to RSV and MPox... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Equiscreen.   From Deadly Flu to RSV and MPox, NNVC's NV-387 Could Be the Only Antiviral That Viruses Can't Escape — Investors Should Take Notice Now! From a deadly RSV season killing children, to influenza infecting millions, and measles spreading at public venues, viruses are creating a global health crisis unlike anything we've seen in decades.  NanoViricides (NYSE: NNVC) may have the solution. Their lead candidate, NV-387, works by tricking viruses into binding with its nanoviricide micelles, destroying them before they infect human cells. Animal studies show complete RSV cures, superior influenza results, and broad activity against coronaviruses, smallpox, and MPox.  Phase I was completed safely, and the Phase II Mpox trial is now authorized in the Democratic Republic of Congo—an essential step toward clinical validation. This is a rare opportunity to discover a potential biotech game-changer.  NV-387 could become the first true broad-spectrum antiviral capable of addressing multiple viral threats simultaneously, putting NNVC at the forefront of a market estimated to exceed $20 billion.  With regulatory clearance, strong preclinical results, and a technology viruses cannot escape, this is the breakout biotech story investors cannot afford to ignore.  Learn how NNVC is leading the antiviral revolution before the world catches on and how this could be rewarding for shareholders We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 03/26/2026 Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.